As the transition period for the UK's departure from the EU ended on Dec 31, 2020, the two parties agreed measures to minimise disruption to the supply of medicines for patients with cancer in the UK and enable continued participation in international clinical trials and research in the short term, but the long-term future impact of Brexit on cancer care and research remains unclear.